Supernus Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Supernus Pharmaceuticals

09/05/2024 17:56

* Supernus Pharmaceuticals Inc  SUPN.OQ  reported quarterly
adjusted earnings of 26 cents​​ per share for the quarter ended
in March, lower than the same quarter last year, when the
company reported EPS of 29 cents.  The mean expectation of
four analysts for the quarter was for earnings of 38 cents per
share. Wall Street expected results to range from 29 cents to 48
cents per share.
    * Revenue fell 6.6% to $143.64 million from a year ago;
analysts
expected $145.83 million. 
    * Supernus Pharmaceuticals Inc's reported EPS for the
quarter was
breakeven results​.
    * The company reported quarterly net income of $124
thousand.
    * Supernus Pharmaceuticals Inc shares had fallen by 8.2%
this
quarter and gained 8.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 1.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Supernus
Pharmaceuticals Inc is $40.50 
This summary was machine generated from LSEG data May 9 at 04:56
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      0.38           0.26           Missed
 Dec. 31 2023      0.55           0.89           Beat
 Sep. 30 2023      0.08           0.24           Beat
 Jun. 30 2023      0.07           -0.02          Missed